BiotechTube
MARAbio

MARAbio

San Diego, United States· Est.
marabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MARAbio is a private, pre-revenue biotech company developing a diagnostic and therapeutic platform for Maternal Autoantibody Related Autism (MARA), an immune-mediated subtype estimated to represent up to 20% of autism cases. Its core asset is a highly predictive maternal blood test designed for use prior to or early in pregnancy, enabling early intervention. The company is leveraging this diagnostic foundation to build a pipeline of proprietary therapeutic antibodies aimed at blocking the pathogenic autoantibodies, positioning itself at the intersection of precision diagnostics and targeted immunology.

Autism Spectrum DisorderNeurodevelopmental Disorders

Technology Platform

Proprietary immunoassay platform to detect a distinct cluster of maternal autoantibodies linked to Maternal Autoantibody Related Autism (MARA). The platform supports diagnostic testing and is being used to develop targeted therapeutic antibodies.

Opportunities

The company addresses a large, unmet need within the autism spectrum disorder market, estimated at up to 20% of cases.
Its early detection test enables proactive family planning and early intervention, while its therapeutic pipeline aims to be first-in-class for a biologically-defined autism subtype, representing a potential paradigm shift in treatment.

Risk Factors

Key risks include the scientific challenge of validating the MARA subtype and developing a safe prenatal therapeutic, the commercial challenge of driving adoption and reimbursement for a predictive test without an immediate treatment, and potential future competition from larger diagnostics or pharmaceutical firms.

Competitive Landscape

MARAbio operates in a niche with limited direct competitors focused on maternal autoantibody diagnostics for autism. Indirect competition includes broad autism genetic testing services and, in the future, developers of anti-FcRn therapies (e.g., argenx, J&J) who may explore the autism indication.

More companies in Diagnostics & Precision Medicine →More companies in United States →